CORE--HYBRIDOMA FACILITY

杂交瘤核心设施将被大约30名UM- RDCC研究人员使用，他们正在进行各种需要单克隆抗体的研究项目。杂交瘤核心的主要目的是产生产生所需特异性单克隆抗体的体细胞杂交瘤。它目前由密歇根糖尿病研究和培训中心（MDRTC）和密歇根大学多用途关节炎中心（UM-MAC）支持，供这些中心的研究人员使用，充电率为20%。它也被其他调查员在充满电的基础上使用。提供的服务包括小鼠免疫，B淋巴细胞与骨髓瘤细胞融合形成杂交瘤，杂交瘤的亚克隆和冷冻保存，小鼠腹水的抗体同型生产，以及体外抗体的生产。在设计免疫策略和筛选试验方面，提供咨询，以确保有效地产生和检测所需的单克隆策略，并进行筛选，以确保有效地产生和检测所需的单克隆抗体。在核心产生的大多数杂交瘤是起源于小鼠，但也产生了大鼠，仓鼠和人类杂交瘤。自1980年成立以来，Hybridoma Facility已经生产了针对多种淋巴细胞表面抗原、肿瘤细胞抗原、肿瘤细胞抗原、纯化蛋白、细胞因子、激素、激素受体和重组蛋白的单克隆抗体。在过去十三年的UM-CAS支持（1988-2000）中，为UM-MAC研究人员进行了200多次融合。在1000多个杂交瘤中进行了亚克隆，并在小鼠腹水中产生了1000多个单克隆抗体批次。在当前的资助周期中，增加了各种专门程序，以满足UM-MAC调查员和未来UM-RDCC调查员的各种需求。目前的提案将允许该学院继续为UM-RDCC实验室提供最新的杂交瘤技术。该中心还将为希望从噬菌体展示库中选择重组抗体样试剂的UM-RDCC研究人员提供协作和咨询服务。通过这些举措，Hybridoma Core将保持在单克隆抗体技术的前沿，并继续为广泛的用户提供最佳服务。

The Hybridoma Core Facility will be used by approximately 30 UM- RDCC investigators who are pursuing a variety of research projects that require monoclonal antibodies. The primary purpose of the Hybridoma Core is to generate somatic-cell hybrids (hybridomas) that produce monoclonal antibodies of desired specificity. It is currently supported by the Michigan Diabetes Research and Training Center (MDRTC), and by the University of Michigan Multipurpose Arthritis Center (UM-MAC), for use by investigators within these centers, t a 20% recharge. It is also used by other investigators on a full recharge basis. Services provided include immunization of mice, fusion of B lymphocytes with myeloma cells to create hybridomas, subcloning and cryopreservation of hybridomas, antibody isotyping production of ascites in mice, and production of antibodies in vitro. Consultation is provided from the Hybridoma Core directors in design of immunization strategies and screening assays to ensure efficient generation and detection of the desired monoclonal strategies and screening to ensure efficient generation and detection of the desired monoclonal antibodies. The majority of hybridomas produced in the core are of murine origin, but rat, hamster and human hybridomas have also been produced. Since its establishment in 1980 the Hybridoma Facility has produced monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, tumor cell antigens, purified proteins, cytokines, hormones, hormone receptors and recombinant proteins. Over the past thirteen years of UM-CAS support (1988-2000) more than 200 fusions were performed for UM-MAC investigators. Subcloning was performed in more than 1000 hybridomas, and more than 1000 monoclonal antibody batches were produced in murine ascites. A variety of specialized procedures have been added during the current funding cycle to address various needs of UM-MAC investigators, and future UM-RDCC investigators. The current proposal will allow this faculty to continue to provide up-to- date hybridoma technology for UM-RDCC laboratories. The core will also provide collaborative and consultative services for the UM-RDCC investigators who may wish to select recombinant antibody-like reagents from phage display libraries. Through these initiatives, the Hybridoma Core will remain on the cutting edge of monoclonal antibody technology, and continued to provide optimal service to a broad range of users.